Anna Malykhina
Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder | 32 | 2024 | 185 | 7.790 |
Why?
| | Lower Urinary Tract Symptoms | 11 | 2022 | 60 | 4.110 |
Why?
| | Potassium Channels, Tandem Pore Domain | 5 | 2024 | 14 | 3.080 |
Why?
| | Urination | 11 | 2024 | 45 | 2.780 |
Why?
| | Muscle, Smooth | 10 | 2024 | 155 | 2.730 |
Why?
| | Muscle Contraction | 14 | 2024 | 424 | 2.730 |
Why?
| | Urinary Bladder, Overactive | 10 | 2021 | 22 | 2.600 |
Why?
| | Pelvic Pain | 4 | 2024 | 33 | 2.400 |
Why?
| | Urinary Bladder, Neurogenic | 4 | 2022 | 38 | 1.800 |
Why?
| | Multiple Sclerosis | 6 | 2022 | 456 | 1.520 |
Why?
| | TRPV Cation Channels | 6 | 2021 | 40 | 1.440 |
Why?
| | Colon | 7 | 2014 | 280 | 1.410 |
Why?
| | Cystitis, Interstitial | 6 | 2021 | 18 | 1.340 |
Why?
| | Coronavirus Infections | 3 | 2022 | 359 | 1.300 |
Why?
| | Chronic Pain | 2 | 2024 | 255 | 1.220 |
Why?
| | Gastrointestinal Diseases | 2 | 2024 | 209 | 1.190 |
Why?
| | Sensory Receptor Cells | 3 | 2022 | 98 | 1.150 |
Why?
| | Urinary Bladder Diseases | 5 | 2019 | 19 | 1.140 |
Why?
| | Erectile Dysfunction | 2 | 2021 | 40 | 1.100 |
Why?
| | Protein Kinase C | 3 | 2015 | 260 | 0.950 |
Why?
| | Murine hepatitis virus | 3 | 2022 | 16 | 0.950 |
Why?
| | Hypertrophy | 3 | 2024 | 132 | 0.920 |
Why?
| | Urinary Bladder Neck Obstruction | 4 | 2023 | 21 | 0.860 |
Why?
| | Colitis | 7 | 2014 | 265 | 0.810 |
Why?
| | Mice, Inbred C57BL | 14 | 2024 | 5744 | 0.790 |
Why?
| | Animals | 39 | 2024 | 36768 | 0.750 |
Why?
| | Pain Perception | 1 | 2022 | 24 | 0.740 |
Why?
| | Lumbosacral Region | 1 | 2022 | 58 | 0.730 |
Why?
| | Administration, Intravesical | 3 | 2017 | 15 | 0.700 |
Why?
| | Urinary Tract Infections | 2 | 2014 | 168 | 0.700 |
Why?
| | Receptor, Muscarinic M3 | 1 | 2020 | 3 | 0.690 |
Why?
| | Receptor, Adenosine A1 | 1 | 2020 | 10 | 0.690 |
Why?
| | Nociception | 1 | 2020 | 16 | 0.690 |
Why?
| | Mice, Knockout | 3 | 2024 | 2999 | 0.680 |
Why?
| | Prostatic Hyperplasia | 1 | 2021 | 42 | 0.680 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2020 | 20 | 0.680 |
Why?
| | Substance P | 4 | 2016 | 36 | 0.670 |
Why?
| | Calcitonin Gene-Related Peptide | 4 | 2016 | 39 | 0.670 |
Why?
| | Neuronal Plasticity | 2 | 2013 | 290 | 0.660 |
Why?
| | Analgesics | 1 | 2022 | 205 | 0.650 |
Why?
| | Coronavirus | 3 | 2022 | 45 | 0.640 |
Why?
| | Hyperalgesia | 1 | 2020 | 123 | 0.630 |
Why?
| | Neuroglia | 1 | 2020 | 172 | 0.620 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2019 | 68 | 0.600 |
Why?
| | Mice | 20 | 2024 | 17731 | 0.570 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2022 | 544 | 0.550 |
Why?
| | Marijuana Smoking | 1 | 2021 | 250 | 0.550 |
Why?
| | Urethra | 1 | 2017 | 55 | 0.550 |
Why?
| | Inflammation | 5 | 2020 | 2834 | 0.540 |
Why?
| | Urodynamics | 5 | 2019 | 44 | 0.530 |
Why?
| | Urogenital System | 1 | 2016 | 17 | 0.510 |
Why?
| | Urinary Tract | 1 | 2016 | 51 | 0.490 |
Why?
| | Diterpenes | 2 | 2012 | 31 | 0.490 |
Why?
| | Cannabinoids | 1 | 2017 | 161 | 0.470 |
Why?
| | Male | 34 | 2024 | 67361 | 0.460 |
Why?
| | Phenotype | 3 | 2019 | 3199 | 0.460 |
Why?
| | Encephalomyelitis | 1 | 2014 | 11 | 0.450 |
Why?
| | Cystitis | 1 | 2014 | 22 | 0.440 |
Why?
| | Estrous Cycle | 1 | 2014 | 20 | 0.440 |
Why?
| | Vincristine | 3 | 2024 | 116 | 0.440 |
Why?
| | Ganglia, Spinal | 5 | 2014 | 77 | 0.430 |
Why?
| | Neuropeptides | 1 | 2014 | 74 | 0.430 |
Why?
| | Marijuana Use | 1 | 2017 | 203 | 0.430 |
Why?
| | Demyelinating Diseases | 1 | 2014 | 85 | 0.430 |
Why?
| | Cyclic Nucleotide-Gated Cation Channels | 2 | 2010 | 15 | 0.410 |
Why?
| | Penis | 1 | 2013 | 36 | 0.410 |
Why?
| | Viscera | 1 | 2012 | 17 | 0.400 |
Why?
| | Disease Models, Animal | 12 | 2022 | 4279 | 0.400 |
Why?
| | Rats, Sprague-Dawley | 8 | 2015 | 2481 | 0.390 |
Why?
| | Neural Pathways | 1 | 2014 | 294 | 0.390 |
Why?
| | Peripheral Nerves | 1 | 2012 | 65 | 0.390 |
Why?
| | Depression | 2 | 2021 | 1402 | 0.380 |
Why?
| | Colonic Diseases | 1 | 2012 | 33 | 0.380 |
Why?
| | Trinitrobenzenesulfonic Acid | 5 | 2012 | 10 | 0.360 |
Why?
| | Motor Neurons | 1 | 2012 | 234 | 0.340 |
Why?
| | Urologic Diseases | 2 | 2024 | 41 | 0.330 |
Why?
| | Color Vision Defects | 1 | 2010 | 8 | 0.330 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2010 | 19 | 0.320 |
Why?
| | Biomarkers | 5 | 2021 | 4158 | 0.320 |
Why?
| | Rats | 8 | 2014 | 5628 | 0.310 |
Why?
| | Protein Subunits | 1 | 2010 | 239 | 0.300 |
Why?
| | Neurons | 3 | 2013 | 1583 | 0.300 |
Why?
| | Doxorubicin | 2 | 2021 | 365 | 0.290 |
Why?
| | Humans | 32 | 2024 | 136783 | 0.280 |
Why?
| | Calcium Channels | 3 | 2021 | 159 | 0.280 |
Why?
| | Female | 24 | 2024 | 72840 | 0.280 |
Why?
| | Central Nervous System | 2 | 2022 | 258 | 0.270 |
Why?
| | Pons | 2 | 2017 | 26 | 0.260 |
Why?
| | Brain-Derived Neurotrophic Factor | 3 | 2021 | 133 | 0.260 |
Why?
| | Lactams, Macrocyclic | 2 | 2017 | 49 | 0.260 |
Why?
| | Benzoquinones | 2 | 2017 | 48 | 0.260 |
Why?
| | Age Factors | 5 | 2024 | 3290 | 0.260 |
Why?
| | Mice, Transgenic | 3 | 2022 | 2162 | 0.260 |
Why?
| | Channelopathies | 1 | 2004 | 5 | 0.220 |
Why?
| | Nerve Growth Factor | 3 | 2021 | 30 | 0.220 |
Why?
| | Mutation | 3 | 2010 | 3953 | 0.210 |
Why?
| | Catastrophization | 2 | 2021 | 16 | 0.210 |
Why?
| | Physical Stimulation | 2 | 2014 | 65 | 0.210 |
Why?
| | Tocotrienols | 1 | 2023 | 3 | 0.210 |
Why?
| | Receptors, Muscarinic | 2 | 2018 | 19 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 849 | 0.200 |
Why?
| | Muscarinic Agonists | 2 | 2020 | 16 | 0.200 |
Why?
| | Fluorescent Antibody Technique | 2 | 2022 | 386 | 0.190 |
Why?
| | Gastrointestinal Tract | 1 | 2004 | 193 | 0.180 |
Why?
| | Signal Transduction | 6 | 2021 | 5065 | 0.180 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 128 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2417 | 0.180 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2021 | 20 | 0.170 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2022 | 343 | 0.170 |
Why?
| | Benzilates | 1 | 2020 | 1 | 0.170 |
Why?
| | Nortropanes | 1 | 2020 | 1 | 0.170 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 2020 | 8 | 0.170 |
Why?
| | Purinergic P1 Receptor Agonists | 1 | 2020 | 8 | 0.170 |
Why?
| | Genes, Synthetic | 1 | 2020 | 15 | 0.170 |
Why?
| | Xanthines | 1 | 2020 | 19 | 0.170 |
Why?
| | Freund's Adjuvant | 1 | 2020 | 18 | 0.170 |
Why?
| | Clozapine | 1 | 2020 | 20 | 0.170 |
Why?
| | Theophylline | 1 | 2020 | 67 | 0.170 |
Why?
| | Touch | 1 | 2020 | 36 | 0.170 |
Why?
| | Constipation | 1 | 2021 | 94 | 0.160 |
Why?
| | Smooth Muscle Myosins | 1 | 2019 | 6 | 0.160 |
Why?
| | Muscle Relaxation | 1 | 2019 | 19 | 0.160 |
Why?
| | Myosin Light Chains | 1 | 2019 | 26 | 0.160 |
Why?
| | Comorbidity | 2 | 2016 | 1611 | 0.160 |
Why?
| | Neurons, Afferent | 2 | 2012 | 97 | 0.150 |
Why?
| | Gene Frequency | 2 | 2018 | 520 | 0.150 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1768 | 0.150 |
Why?
| | RNA-Binding Proteins | 1 | 2022 | 424 | 0.150 |
Why?
| | Receptors, Purinergic P2X1 | 1 | 2018 | 3 | 0.150 |
Why?
| | Cholinergic Fibers | 1 | 2018 | 18 | 0.150 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2019 | 130 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 220 | 0.150 |
Why?
| | Spinal Cord | 2 | 2014 | 369 | 0.140 |
Why?
| | Recombinant Fusion Proteins | 1 | 2020 | 663 | 0.140 |
Why?
| | White Matter | 1 | 2019 | 145 | 0.140 |
Why?
| | Caveolins | 1 | 2017 | 5 | 0.140 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2019 | 379 | 0.140 |
Why?
| | Hot Temperature | 1 | 2020 | 392 | 0.140 |
Why?
| | Severity of Illness Index | 4 | 2021 | 2831 | 0.140 |
Why?
| | Urinary Incontinence, Urge | 1 | 2017 | 2 | 0.140 |
Why?
| | Lumbosacral Plexus | 2 | 2017 | 6 | 0.130 |
Why?
| | Brain Stem | 1 | 2017 | 94 | 0.130 |
Why?
| | Postmenopause | 2 | 2016 | 365 | 0.130 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 24 | 0.130 |
Why?
| | Reflex | 2 | 2018 | 68 | 0.130 |
Why?
| | Cancer Survivors | 1 | 2021 | 279 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2024 | 2045 | 0.130 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 45 | 0.130 |
Why?
| | Cytoskeleton | 1 | 2017 | 186 | 0.120 |
Why?
| | Electric Stimulation | 3 | 2012 | 264 | 0.120 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 1250 | 0.120 |
Why?
| | Pilot Projects | 2 | 2019 | 1697 | 0.120 |
Why?
| | Phorbol 12,13-Dibutyrate | 1 | 2015 | 8 | 0.120 |
Why?
| | Phorbol Esters | 1 | 2015 | 14 | 0.120 |
Why?
| | Polymorphism, Genetic | 1 | 2018 | 657 | 0.120 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 432 | 0.120 |
Why?
| | Sex Factors | 2 | 2024 | 2068 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2017 | 260 | 0.120 |
Why?
| | Pituitary-Adrenal System | 1 | 2016 | 162 | 0.110 |
Why?
| | RNA, Small Interfering | 1 | 2017 | 621 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 657 | 0.110 |
Why?
| | Pyuria | 1 | 2014 | 4 | 0.110 |
Why?
| | Brain Diseases | 1 | 2016 | 141 | 0.110 |
Why?
| | Bacteriuria | 1 | 2014 | 10 | 0.110 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2016 | 197 | 0.110 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 241 | 0.110 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1731 | 0.110 |
Why?
| | Time Factors | 3 | 2021 | 6792 | 0.110 |
Why?
| | Carbachol | 2 | 2011 | 20 | 0.110 |
Why?
| | Alcohol Drinking | 1 | 2021 | 818 | 0.110 |
Why?
| | Nerve Growth Factors | 1 | 2014 | 79 | 0.110 |
Why?
| | Peroxidase | 1 | 2014 | 176 | 0.110 |
Why?
| | Aging | 1 | 2024 | 1861 | 0.100 |
Why?
| | Adult | 8 | 2021 | 37616 | 0.100 |
Why?
| | Potassium Channels | 1 | 2014 | 150 | 0.100 |
Why?
| | Genotype | 1 | 2018 | 1919 | 0.100 |
Why?
| | Voltage-Gated Sodium Channels | 1 | 2012 | 5 | 0.100 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channels | 1 | 2012 | 11 | 0.100 |
Why?
| | Afferent Pathways | 1 | 2013 | 45 | 0.100 |
Why?
| | Cholinergic Neurons | 1 | 2012 | 17 | 0.100 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 140 | 0.100 |
Why?
| | Blotting, Western | 2 | 2012 | 1225 | 0.100 |
Why?
| | Organ Culture Techniques | 1 | 2013 | 155 | 0.100 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1089 | 0.100 |
Why?
| | Case-Control Studies | 3 | 2019 | 3537 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 7583 | 0.090 |
Why?
| | Cholinergic Agents | 1 | 2011 | 18 | 0.090 |
Why?
| | Premenopause | 1 | 2011 | 131 | 0.090 |
Why?
| | Cytokines | 1 | 2019 | 2088 | 0.090 |
Why?
| | Data Interpretation, Statistical | 1 | 2012 | 349 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2190 | 0.090 |
Why?
| | Proteomics | 1 | 2017 | 1108 | 0.080 |
Why?
| | Neuralgia | 1 | 2011 | 133 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5115 | 0.080 |
Why?
| | Mutant Proteins | 1 | 2010 | 101 | 0.080 |
Why?
| | Ion Channel Gating | 1 | 2010 | 89 | 0.080 |
Why?
| | Incidence | 1 | 2016 | 2788 | 0.080 |
Why?
| | Models, Animal | 1 | 2011 | 384 | 0.080 |
Why?
| | Middle Aged | 8 | 2021 | 33200 | 0.080 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 309 | 0.080 |
Why?
| | Recurrence | 1 | 2011 | 1058 | 0.070 |
Why?
| | Protein Transport | 1 | 2010 | 442 | 0.070 |
Why?
| | Acute Disease | 1 | 2011 | 1006 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 973 | 0.070 |
Why?
| | Quality of Life | 3 | 2021 | 2868 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2012 | 738 | 0.070 |
Why?
| | Brain | 1 | 2019 | 2669 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4018 | 0.070 |
Why?
| | Stress, Psychological | 1 | 2016 | 1098 | 0.070 |
Why?
| | src-Family Kinases | 2 | 2007 | 92 | 0.070 |
Why?
| | HEK293 Cells | 1 | 2010 | 728 | 0.070 |
Why?
| | Trinucleotide Repeats | 1 | 2006 | 25 | 0.060 |
Why?
| | Trinucleotide Repeat Expansion | 1 | 2006 | 29 | 0.060 |
Why?
| | Risk Assessment | 1 | 2016 | 3429 | 0.060 |
Why?
| | Irritable Bowel Syndrome | 1 | 2006 | 26 | 0.060 |
Why?
| | Tyrosine | 1 | 2007 | 222 | 0.060 |
Why?
| | Iron-Binding Proteins | 1 | 2006 | 44 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2644 | 0.060 |
Why?
| | Sacrum | 1 | 2005 | 79 | 0.060 |
Why?
| | Cerebellum | 1 | 2006 | 224 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2007 | 434 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2005 | 245 | 0.050 |
Why?
| | Aged | 4 | 2017 | 23729 | 0.050 |
Why?
| | Ion Channels | 1 | 2004 | 132 | 0.050 |
Why?
| | Electrophysiology | 3 | 2010 | 217 | 0.050 |
Why?
| | Action Potentials | 1 | 2006 | 495 | 0.050 |
Why?
| | Mast Cells | 1 | 2024 | 146 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2024 | 190 | 0.050 |
Why?
| | RNA, Messenger | 1 | 2010 | 2831 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2019 | 1267 | 0.050 |
Why?
| | Child, Preschool | 1 | 2016 | 11069 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5417 | 0.040 |
Why?
| | Osteopontin | 1 | 2021 | 33 | 0.040 |
Why?
| | Visual Analog Scale | 1 | 2021 | 33 | 0.040 |
Why?
| | Models, Biological | 2 | 2010 | 1769 | 0.040 |
Why?
| | Child | 2 | 2021 | 21968 | 0.040 |
Why?
| | Administration, Oral | 1 | 2023 | 808 | 0.040 |
Why?
| | Interleukin-2 | 1 | 2022 | 454 | 0.040 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2019 | 8 | 0.040 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2019 | 20 | 0.040 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2019 | 10 | 0.040 |
Why?
| | Anxiety, Separation | 1 | 2018 | 16 | 0.040 |
Why?
| | Maternal Deprivation | 1 | 2018 | 16 | 0.040 |
Why?
| | Risk Factors | 1 | 2011 | 10331 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 843 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3566 | 0.030 |
Why?
| | Young Adult | 1 | 2011 | 13126 | 0.030 |
Why?
| | Bethanechol | 1 | 2014 | 1 | 0.030 |
Why?
| | Atropine | 1 | 2014 | 23 | 0.030 |
Why?
| | Muscarinic Antagonists | 1 | 2014 | 28 | 0.030 |
Why?
| | Phosphorylation | 1 | 2019 | 1756 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2011 | 15564 | 0.030 |
Why?
| | Health Surveys | 1 | 2016 | 517 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2016 | 317 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 5749 | 0.030 |
Why?
| | Phenanthrenes | 1 | 2012 | 13 | 0.030 |
Why?
| | Carboxylic Acids | 1 | 2012 | 34 | 0.020 |
Why?
| | Calcium | 2 | 2010 | 1197 | 0.020 |
Why?
| | Adolescent | 1 | 2011 | 21463 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2014 | 486 | 0.020 |
Why?
| | Heart Rate | 1 | 2016 | 823 | 0.020 |
Why?
| | Intestinal Diseases | 1 | 2011 | 41 | 0.020 |
Why?
| | Benzimidazoles | 1 | 2012 | 168 | 0.020 |
Why?
| | Rabbits | 1 | 2012 | 789 | 0.020 |
Why?
| | Adaptation, Psychological | 1 | 2016 | 651 | 0.020 |
Why?
| | Circular Dichroism | 1 | 2010 | 150 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 345 | 0.020 |
Why?
| | Protein Stability | 1 | 2010 | 177 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 838 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2010 | 376 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 322 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2010 | 573 | 0.020 |
Why?
| | Anxiety | 1 | 2016 | 1032 | 0.020 |
Why?
| | Cholinergic Agonists | 1 | 2007 | 6 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2007 | 38 | 0.020 |
Why?
| | Nitric Acid | 1 | 2007 | 5 | 0.020 |
Why?
| | Enema | 1 | 2007 | 47 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2007 | 125 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1354 | 0.020 |
Why?
| | Dextran Sulfate | 1 | 2005 | 83 | 0.020 |
Why?
| | Escherichia coli | 1 | 2010 | 812 | 0.020 |
Why?
| | Friedreich Ataxia | 1 | 2006 | 75 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7569 | 0.010 |
Why?
| | Cell Line | 1 | 2010 | 2836 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 888 | 0.010 |
Why?
| | Recovery of Function | 1 | 2007 | 655 | 0.010 |
Why?
|
|
Malykhina's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|